small molecule

SPIRIVA RESPIMAT

TIOTROPIUM BROMIDE

Loss of exclusivityApril 2031latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameSPIRIVA RESPIMAT
Active ingredientTIOTROPIUM BROMIDE
StrengthEQ 0.0025MG BASE/INH
Dosage formSPRAY, METERED
RouteINHALATION
ModalitySmall molecule
FDA approvalSeptember 2014
Marketing statusRX

Listed patents

PatentExpiresType
8733341*PEDApril 2031—
8733341October 2030product
7837235*PEDSeptember 2028—
7837235March 2028product
9027967*PEDSeptember 2027—
7396341*PEDApril 2027—
9027967March 2027product
7396341October 2026product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.